Gene Therapy Breakthroughs Will Unlock Expanding Future Markets

Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.

Shared on 01 May 25

Fair value Decreased 48%

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

Shared on 24 Apr 25

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.51%

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 37.2x to 41.2x.

Shared on 09 Apr 25

Fair value Increased 93%

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 1.05%